This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Comprehensive validation of published immunohistochemical prognostic biomarkers of prostate cancer—what has gone wrong? A blueprint for the way forward in biomarker studies
British Journal of Cancer Open Access 25 November 2014
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Thompson IM et al. (2004) Prevalence of prostate cancer among men with a prostate-specific antigen level ≤4.0 ng per milliliter. N Engl J Med 350: 2239–2246
Stamey TA et al. (2004) The prostate specific antigen era in the United States is over for prostate cancer: what happened in the last 20 years? J Urol 170: 1297–1301
Antenor JA et al. (2004) Relationship between initial prostate specific antigen level and subsequent prostate cancer detection in a longitudinal screening study. J Urol 172: 90–93
Bill-Axelson A et al. (2005) Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 352: 1977–1984
Albertsen PC et al. (1998) Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer. JAMA 280: 975–980
Acknowledgements
The synopsis was written by Tamsin Osborne, Assistant Editor, Nature Clinical Practice.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The author declares no competing financial interests.
Rights and permissions
About this article
Cite this article
Klotz, L. Can clinically localized prostate cancer be managed conservatively?. Nat Rev Urol 2, 416–417 (2005). https://doi.org/10.1038/ncpuro0292
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/ncpuro0292
This article is cited by
-
Comprehensive validation of published immunohistochemical prognostic biomarkers of prostate cancer—what has gone wrong? A blueprint for the way forward in biomarker studies
British Journal of Cancer (2015)
-
Comparison of prognostic values between combined immunohistochemical score of estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2, Ki-67 and the corresponding gene expression score in breast cancer
Modern Pathology (2013)